Efficacy of ustekinumab in sub-erythrodermic psoriasis: When TNF-blockers fail

Dermatologic Therapy

Volumn 25, Issue 3, 2012, Pages 283-285

  Buggiani, Gionata ^a   D'Erme, Angelo Massimiliano ^b   Krysenka, Alena ^b   Pescitelli, Leonardo ^b   Lotti, Torello ^a   Prignano, Francesca ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

biologics; erythrodermia; psoriasis; ustekinumab

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; ETRETINATE; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHRODERMA; ERYTHRODERMIC PSORIASIS; HEALTH STATUS; HOSPITALIZATION; HUMAN; INFORMED CONSENT; MALE; PHOTOTHERAPY; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; SHORT SURVEY; ULTRAVIOLET B RADIATION;

ANTIBODIES, MONOCLONAL; BIOLOGICAL AGENTS; DERMATITIS, EXFOLIATIVE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865478043     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2012.01465.x     Document Type: Short Survey

References (5)

1. Meier M, Sheth PB,. Clinical spectrum and severity of psoriasis. Curr Probl Dermatol 2009: 38: 1-20.
2. Kircik LH, Gonzalez ME,. How and when to use biologics in psoriasis. J Drugs Dermatol 2010: 9 (8 Suppl. ODAC Conf Pt 2): s106-s117.
3. Yeilding N, Szapary P, Brodmerkel C, et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci 2011: 1222: 30-39.
4. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009: 373 (9664): 633-640.
5. Vitiello M, Grant A, Kerdel FA,. Ustekinumab: when everything else fails? Int J Dermatol 2011: 50 (4): 478-482.